UTv Videos

“But more importantly, there are patients who have no insurance, there are patients who have no other resources and are maybe even on the poverty line. We feel, importantly, that we have an obligation that the drug be made free for these patients in the United States,” says Patrick Soon-Shiong, MD.

"We found that the GetWell patients have shown increases in their Wisconsin Stone Quality of Life scores, or the WISQOL score, of about 3 points from baseline to 6 months," says Jenny Guo, MD.

"In the study, about two thirds of the residents did undergo PNE and one third underwent Stage 1, and those who underwent PNE were less likely to progress to device implant than Stage 1," says Leo Dreyfuss, MD.

"In our commercial all-comers cohort of patients undergoing Aquablation, efficacy was similar to and safety was improved compared to the WATER I and WATER II clinical trials," says Shawn H. Marhamati, MD, MS.

"One of the main summaries/focuses of this discussion was, how do we create action to improve screening, and what that actually means," says Samuel L. Washington III, MD, MAS.

"[The care plan] incorporates patient-specific data to reinforce dietary management, fluid intake, and medication adherence based on the patient's 24-hour urine collection results," says Jenny Guo, MD.

"So I think these findings overall are reassuring and support the use of neuromodulation in this population," says Leo Dreyfuss, MD.

“Along those lines, we've taken away the traditional step therapy that has dictated overactive bladder care for quite some time,” says Ariana L. Smith, MD, FPMRS.

“The 2018 AUA guidelines for testosterone therapy that were co-chaired by Dr. John P. Mulhall say that we have an absence or a paucity of data on using testosterone therapy on active surveillance,” says Helen L. Bernie, DO, MPH.

"We did discuss a couple of future research ideas, a number of which would have been controlling for those potential factors we thought could contribute to the increased UTI risk that we were not able to control for in the study like loss of commensal bacteria or anything of that nature," says David Gilbert.

"But more excitingly, as early as 9 months, even though they were small numbers, the comparison between BCG and Anktiva vs BCG alone showed a statistical significance in the duration of ongoing complete response," says Patrick Soon-Shiong, MD.

"The wide variability that we found across MUSIC practices suggests an opportunity for us for quality improvement initiatives and additional evidence surrounding who should receive secondary treatment and what modalities," says Daniel A. Triner, MD, PhD.

"I think right now, a lot of the focus is on perioperative management, as well as some of the technical considerations of the surgery itself," says Jay Simhan, MD, FACS.

"We found that approximately 2 out of every 3 patients with node-positive disease go on to some form of secondary treatment within 12 months," says Daniel A. Triner, MD, PhD.

"We're doing a lot of active surveillance, and it's good to know that most of these people are getting the appropriate care that they should receive," says Yuzhi (Katherine) Wang, MD.

“Also, the technique lends itself really nicely to these, what we call posterior ball-valve tumors, which are these tumors that sit behind the renal hilum, behind the blood vessels on the posterior side of the kidney,” says Alexander Kutikov, MD, FACS.

“All this is very detailed immunology, I get that, but it sets the stage for what I consider the next evolution of immunotherapy,” says Patrick Soon-Shiong, MD.

"There's definitely more work to do to confirm these results on a multi-institutional aspect," says Ryan L. Steinberg, MD.

In this video, 4 experts discuss the highlights and take-home messages from the 2024 American Urological Association Annual Meeting.

“What we need is continued work on integrating surgery and systemic therapy,” says Patrick Kenney, MD.

"We've developed the Get Moving Trial, which is a randomized controlled phase 1/2 trial to demonstrate the safety, feasibility and efficacy of a home-based pre-op program that is personalized," says Sarah P. Psutka, MD, MSc.

"So, in the MoonRISe-1 study, we're studying the efficacy of TAR-210 to prevent recurrence within the bladder by inserting the TAR-210 in the bladder every 3 months for up to 1 year, compared to intravesical chemotherapy," says Roger Li, MD.

Roger R. Dmochowski, MD, MMHC, highlights the FDA approval of the Revi System, specifically touching on how the device may be used as a potential earlier line of therapy for patients with OAB.

Angela B. Smith, MD, MS, highlights key takeaways from the session, “Time Efficiency and Productivity Hacks for the Busy Urologist,” which was presented at the 2024 AUA Annual Meeting.

"BCG worked well enough that we could give it to patients and it worked pretty well. But having the shortage, I think, has ultimately led to a bottleneck and then an explosion in the technology and the resources and the techniques to treat patients with non–muscle-invasive bladder cancer," says Joshua J. Meeks, MD, PhD.

“We can all learn and collaborate from each other, that way we can continue to provide really great care for our patients,” says Mary W. Dunn, MSN, NP-C, OCN, RN.

Mark D. Tyson, II, MD, MPH, shares interim findings from the BOND-003 trial, evaluating cretostimogene grenadenorepvec in patients with high risk, papillary only, BCG-unresponsive non–muscle-invasive bladder cancer.